Stocktoria
CervoMed Inc. CRVO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-11-09
CervoMed Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.0M | $9.7M | $7.1M | $0 | — |
| R&D expense | $21.8M | $18.8M | $8.4M | $1.3M | $8.5M |
| Operating income | -$28.3M | -$18.2M | -$7.8M | -$3.5M | -$24.7M |
| Interest expense | — | — | $0 | $587 | — |
| Income tax | $0 | — | — | $0 | -$443,893 |
| Net income | -$27.0M | -$16.3M | -$2.2M | -$5.8M | -$24.1M |
| EPS (diluted) | — | — | — | $2038891.00 | $1946859.00 |
| Operating cash flow | -$23.4M | -$16.5M | -$7.4M | -$2.6M | -$14.5M |
| Cash & equivalents | $8.2M | $9.0M | $7.8M | $4.1M | $37.3M |
| Total assets | $22.9M | $43.1M | $10.0M | $4.2M | $37.8M |
| Total liabilities | $4.7M | $3.9M | $2.6M | $13.2M | $2.9M |
| Shareholders' equity | $18.2M | $39.2M | $7.4M | -$33.3M | $34.9M |
Source: SEC EDGAR filings · CIK 0001053691 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.